Topics:
Radiation Oncology • Gastrointestinal Cancers • Gastric Cancer • Esophageal Cancer • Medical Oncology • Journal Club ft. NEJM publications
Can CM577 regimen of adjuvant nivolumab s/p neoadjuvant chemoRT with residual disease following surgery be extrapolated to patients with R1 resection unable to undergo re-resection?
CheckMate 577 only included patients with R0 resection.
For R1 resections, guidelines suggest observation vs re-resection only.
Answer from: Medical Oncologist at Academic Institution
This is an excellent question and, of course, one for which there are no data. So, unburdened by data, I'm free to offer my personal opinion. I think all of us would value other comments and responses to this question as well.I think that this question also applies to those patients who achieve a cl...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
While CheckMate 577 was not designed to answer this question, my inclination is that adjuvant nivolumab could help patients who had an R1 resection and I would strongly consider this approach. However, prior to starting a patient who underwent an R1 resection on adjuvant nivolumab, I think these pat...
Answer from: Medical Oncologist at Academic Institution
Unfortunately, all patients that enrolled in CM577 had an R0 surgical resection so we do not have data on the role of adjuvant PD-1 inhibitors in those patients who had an R1 resection.